Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells DexCom, Aerie Pharmaceuticals, Depomed

• New Purchases: GLPG, AVDL, ACOR, IRTC, CTMX, BCRX, ATRS, JAZZ, ALNY, PPHMP,
• Added Positions: NBIX, ACRS, FOLD, ANIP, AVXS, GBT, ARDX, VBIV, ZGNX, XNCR,
• Reduced Positions: SRPT, AERI, CRBP, ABMD, SUPN, AGEN, BPMC, NDRM, AGTC, CEMP,
• Sold Out: DXCM, DEPO, ACHN, PTI, AMRN, ANTH, CLLS, BGNE, MYL, ACAD,

For the details of PERCEPTIVE ADVISORS LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERCEPTIVE+ADVISORS+LLC

1. Neurocrine Biosciences Inc (NBIX) - 3,316,523 shares, 9.2% of the total portfolio. Shares added by 33.93%
2. Tesaro Inc (TSRO) - 687,993 shares, 6.63% of the total portfolio. Shares added by 0.82%
3. Amicus Therapeutics Inc (FOLD) - 17,296,672 shares, 6.16% of the total portfolio. Shares added by 22.53%
4. Sarepta Therapeutics Inc (SRPT) - 2,769,829 shares, 5.44% of the total portfolio. Shares reduced by 18.42%
5. Versartis Inc (VSAR) - 4,153,685 shares, 4.43% of the total portfolio. Shares added by 3.10%

Perceptive Advisors Llc initiated holdings in Galapagos NV. The purchase prices were between $57.96 and $66.8, with an estimated average price of $61.54. The stock is now traded at around $74.84. The impact to the portfolio due to this purchase was 1.48%. The holdings were 304,531 shares as of 2016-12-31.

Perceptive Advisors Llc initiated holdings in Avadel Pharmaceuticals PLC. The purchase prices were between $9.26 and $13.16, with an estimated average price of $10.99. The stock is now traded at around $10.16. The impact to the portfolio due to this purchase was 1.03%. The holdings were 1,388,240 shares as of 2016-12-31.

Perceptive Advisors Llc initiated holdings in Acorda Therapeutics Inc. The purchase prices were between $16.45 and $21.7, with an estimated average price of $19.81. The stock is now traded at around $27.85. The impact to the portfolio due to this purchase was 0.97%. The holdings were 720,000 shares as of 2016-12-31.

Perceptive Advisors Llc initiated holdings in iRhythm Technologies Inc. The purchase prices were between $23.08 and $30.94, with an estimated average price of $26.94. The stock is now traded at around $35.60. The impact to the portfolio due to this purchase was 0.76%. The holdings were 352,241 shares as of 2016-12-31.

Perceptive Advisors Llc initiated holdings in CytomX Therapeutics Inc. The purchase prices were between $10.21 and $15.89, with an estimated average price of $12.12. The stock is now traded at around $13.53. The impact to the portfolio due to this purchase was 0.73%. The holdings were 923,763 shares as of 2016-12-31.

Perceptive Advisors Llc initiated holdings in Biocryst Pharmaceuticals Inc. The purchase prices were between $3.76 and $6.99, with an estimated average price of $5.2. The stock is now traded at around $8.46. The impact to the portfolio due to this purchase was 0.6%. The holdings were 1,330,240 shares as of 2016-12-31.

Perceptive Advisors Llc added to the holdings in Neurocrine Biosciences Inc by 33.93%. The purchase prices were between $37.9 and $54.77, with an estimated average price of $45.27. The stock is now traded at around $44.61. The impact to the portfolio due to this purchase was 2.33%. The holdings were 3,316,523 shares as of 2016-12-31.

Perceptive Advisors Llc added to the holdings in Aclaris Therapeutics Inc by 193.22%. The purchase prices were between $20.53 and $31.25, with an estimated average price of $25.5. The stock is now traded at around $31.50. The impact to the portfolio due to this purchase was 1.61%. The holdings were 1,260,847 shares as of 2016-12-31.

Perceptive Advisors Llc added to the holdings in Amicus Therapeutics Inc by 22.53%. The purchase prices were between $4.53 and $9.35, with an estimated average price of $6.92. The stock is now traded at around $7.34. The impact to the portfolio due to this purchase was 1.13%. The holdings were 17,296,672 shares as of 2016-12-31.

Perceptive Advisors Llc added to the holdings in ANI Pharmaceuticals Inc by 2210.35%. The purchase prices were between $47.51 and $68.96, with an estimated average price of $61.15. The stock is now traded at around $48.79. The impact to the portfolio due to this purchase was 1.11%. The holdings were 267,100 shares as of 2016-12-31.

Perceptive Advisors Llc added to the holdings in AveXis Inc by 149.23%. The purchase prices were between $42 and $71.36, with an estimated average price of $53.44. The stock is now traded at around $71.76. The impact to the portfolio due to this purchase was 0.97%. The holdings were 473,531 shares as of 2016-12-31.

Perceptive Advisors Llc added to the holdings in Global Blood Therapeutics Inc by 34.05%. The purchase prices were between $13.9 and $22.5, with an estimated average price of $17.57. The stock is now traded at around $36.81. The impact to the portfolio due to this purchase was 0.82%. The holdings were 3,128,978 shares as of 2016-12-31.

Perceptive Advisors Llc sold out the holdings in DexCom Inc. The sale prices were between $59.7 and $84.98, with an estimated average price of $70.86.

Perceptive Advisors Llc sold out the holdings in Depomed Inc. The sale prices were between $17.59 and $26.01, with an estimated average price of $21.23.

Perceptive Advisors Llc sold out the holdings in Achillion Pharmaceuticals Inc. The sale prices were between $3.97 and $8.08, with an estimated average price of $5.32.

Perceptive Advisors Llc sold out the holdings in Proteostasis Therapeutics Inc. The sale prices were between $6.87 and $15.67, with an estimated average price of $11.66.

Perceptive Advisors Llc sold out the holdings in Amarin Corp PLC. The sale prices were between $2.75 and $3.47, with an estimated average price of $3.18.

Perceptive Advisors Llc sold out the holdings in Anthera Pharmaceuticals Inc. The sale prices were between $0.65 and $3.32, with an estimated average price of $2.16.

Perceptive Advisors Llc reduced to the holdings in Aerie Pharmaceuticals Inc by 87.71%. The sale prices were between $32.8 and $42.2, with an estimated average price of $37.82. The stock is now traded at around $48.65. The impact to the portfolio due to this sale was -0.89%. Perceptive Advisors Llc still held 50,000 shares as of 2016-12-31.

Perceptive Advisors Llc reduced to the holdings in Corbus Pharmaceuticals Holdings Inc by 58.06%. The sale prices were between $4.8 and $9.79, with an estimated average price of $7.64. The stock is now traded at around $9.05. The impact to the portfolio due to this sale was -0.7%. Perceptive Advisors Llc still held 1,132,684 shares as of 2016-12-31.

Perceptive Advisors Llc reduced to the holdings in Abiomed Inc by 99.83%. The sale prices were between $102.51 and $131.74, with an estimated average price of $115.85. The stock is now traded at around $120.03. The impact to the portfolio due to this sale was -0.53%. Perceptive Advisors Llc still held 109 shares as of 2016-12-31.

Perceptive Advisors Llc reduced to the holdings in Supernus Pharmaceuticals Inc by 99.83%. The sale prices were between $17.85 and $26.1, with an estimated average price of $22.34. The stock is now traded at around $27.70. The impact to the portfolio due to this sale was -0.4%. Perceptive Advisors Llc still held 421 shares as of 2016-12-31.

Perceptive Advisors Llc reduced to the holdings in Agenus Inc by 91.98%. The sale prices were between $3.73 and $7.36, with an estimated average price of $5. The stock is now traded at around $4.07. The impact to the portfolio due to this sale was -0.39%. Perceptive Advisors Llc still held 72,187 shares as of 2016-12-31.

Perceptive Advisors Llc reduced to the holdings in Blueprint Medicines Corp by 40.48%. The sale prices were between $25.58 and $38.06, with an estimated average price of $30.14. The stock is now traded at around $36.02. The impact to the portfolio due to this sale was -0.36%. Perceptive Advisors Llc still held 273,820 shares as of 2016-12-31.